pramipexole + rasagiline

Pramipexole + rasagiline is a fixed-dose, extended-release oral combination therapy developed for the treatment of Parkinson's disease. Pramipexole is a dopamine agonist that directly stimulates dopamine receptors in the brain, while rasagiline is an irreversible monoamine oxidase B (MAO-B) inhibitor that increases extracellular dopamine levels by inhibiting its breakdown. The combination aims to improve striatal dopaminergic transmission through distinct and potentially synergistic mechanisms, offering enhanced efficacy and improved tolerability compared to either agent alone. Clinical studies have shown that this low-dose combination provides significant symptomatic benefit with fewer side effects such as daytime sleepiness, orthostatic hypotension, and memory impairment compared to standard doses of individual components. The product does not require titration and is administered once daily[1][2][3][7].

Brand names

P2B001P-2B001P 2B001

Other names

pramipexole and rasagiline extended-releasepramipexole/rasagiline combination